← Back
Research Paper Volume 15, Issue 9 pp 3331—3355

In vitro and in vivo effects of zoledronic acid on senescence and senescence-associated secretory phenotype markers

class="figure-viewer-img"

Figure 3. Effects of zoledronic acid on senescence markers in bone. (A) Zoledronic acid treatment led a significant downregulation of Cdkn1a/p21Cip1, but not Cdkn2a/p16Ink4a in the centrifuged metaphyses, enriched for osteocytes (see Methods). (B) Example of an osteocyte with γH2A.X (green) and telomeres (red); where they colocalize, a TAF is scored (yellow). (C) Mean #TAF/osteocyte, (D) percentage of osteocytes with ≥ 1, 2, or 3 TAF/osteocyte. p-values are using Mann-Whitney test; n = 14 Veh and n=13 Zol mice per group (A, B) and n=10/group (B–D).